Please login to the form below
Advanced Accelerator Applications
This page shows the latest Advanced Accelerator Applications news and features for those working in and with pharma, biotech and healthcare.
Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
Novartis has revealed new data from a phase 3 trial evaluating its targeted radioligand therapy (RLT) in late stage advanced prostate cancer at the 2021 American Society of Clinical Oncology (ASCO) ... outcomes,” said Alessandra Dorigo, general manager
Latest news
-
Novartis chooses internal replacement for US pharma president role
She joined the company from Advanced Accelerator Applications after it was acquired by Novartis and has also served as the head of pharmaceuticals for Europe at the company.
-
Novartis buys cancer specialist Endocyte for $2.1bn
177. Lu- oxodotreotide) for gastroenteropancreatic neuroendocrine (GEP-NET) tumours, acquired along with French company Advanced Accelerator Applications for $3.9bn a year ago.
-
Novartis follows Pfizer and freezes US prices this year
ploughing the cash back into the pipeline-enriching acquisitions of gene therapy company AveXis and radiopharma specialist Advanced Accelerator Applications – and going ahead with the spin-off its Alcon eyecare unit.
-
AAA board presses go on $3.9bn Novartis takeover
French radiopharmaceuticals firm backs the cash offer. Novartis has started its cash tender offer for French firm Advanced Accelerator Applications, which specialises in radiopharmaceuticals to treat cancer.
-
Novartis to buy French radiopharma specialist AAA for $3.9bn
Novartis has agreed a $3.9bn deal to buy Advanced Accelerator Applications, a French company specialising in nuclear medicines used to treat tumours. ... The transaction gives Novartis “both near-term product launches as well as a new technology
More from news
Approximately 2 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Abeona Therapeutics appoints new additions to board of directors
Buono was previously the chief executive officer and president of Advanced Accelerator Applications, an international radiopharmaceutical company he founded in 2002.
-
Former Roche development head joins Asana advisory board
The founder of KAPital Consulting, Dr Dhingra currently serves on the boards of Exosome Diagnostics as chairman of the board, Advanced Accelerator Applications, Five Prime and Autolus.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Medscape Medical Affairs
Medscape Medical Affairs enables all medical affairs professionals to take a more strategic leadership role, and maximize the impact of...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
